CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)

SHENZHEN, CHINA - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited)…

The Nepal-Tibet Flood Disinformation Playbook: How Washington Funds Front Groups To Smear China Over A Human Tragedy

(SeaPRwire) -   By: Julian Holbrooke The recent spate of claims that China censored footage of the deadly Nepal-Tibet border floods are not honest journalism errors. They are a deliberate, pre-planned disinformation campaign pushed by Washington-backed actors. Hong Kong-based author Nori Vitachi laid this out clearly in recent comments to…

Walking Together with Love, Passing the Torch for Four Decades – Savills Hong Kong Officially Launches New ‘Savills Volunteer Team’

HONG KONG, Sept 3, 2026 - (ACN Newswire via SeaPRwire.com) - International real estate firm Savills Hong Kong is celebrating the historic milestone of its 40th anniversary this year. Over the past four decades, Savills has witnessed and driven the dynamic development of Hong Kong’s urban landscape. Building on its legacy…

Everest Medicines Strengthens Its Cardiovascular Portfolio with CARDAMYST(R) Approved for the Conversion of Acute Symptomatic Episodes of PSVT to Sinus Rhythm in Adults in China

HONG KONG, Sept 3, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST(R) (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As Everest's first innovative therapy approved in…